PARP12 and breast cancer: While a deficiency of PARP12 in HCC was found to beassociated with a promotion of migration and invasion of HCC,143 in other tumors it seems to be highly upregulated.144 In particular, it was recently reported thatin MCF7 breast cancer cell lines PARP12 silencing potentiated theeffect of the alkylating agent mafosfamide by reducing cell survivaland cancer regrowth.144 In the latter case,the use of a PARP12 inhibitor could be a good selective strategy tocounteract the cancer proliferation.